Immunological Consequences of COVID-19 Vaccination in Patients with Rheumatic Diseases


About this study

This research trial will study the immune respone to COVID-19 vaccination in patients with rheumatic diseases.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Rheumatologist confirmed diagnosis of one of the following diagnoses:
    • Systemic lupus erythematosus;
    • Sjogren syndrome;
    • Inflammatory myositis;
    • Psoriatic arthritis;
    • Osteoarthritis;
    • Gout;
    • Ankylosing spondylitis;
    • IBD-related arthritis.

Exclusion Criteria: 

  • Active infection or untreated malignancy (other than skin cancer) at enrollment.
  • Pregnancy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Hu Zeng, Ph.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer